Replies to post #360345 on Anavex Life Sciences Corp (AVXL)

[BIOChecker4]

It would be better if Missling would focus on getting one or two things over the goal line so some big pharma would buy the company at a substantial premium and put the resources into the company necessary to actually realize the further pipeline potential. By design, Missling is in the way.

[nidan7500]

IMO, the patent is about diagnostics, analysis and follow on treatment related to testing. Agree it seems likely other treatments (ex. A xxx) might follow a specified variant sequence and defined treatment protocol.

IMO, this is a variation of ..."take 2 of these and call me in a week." . It's about being more precise with subject analysis and corresponding S1R treatments.

They are zeroing in on custom medicine for each subject by applying unspecified analysis and corresponding treatment, but all w/in the S1R MOA envelope.